IDRA

Idera PharmaceuticalsNasdaqCM:IDRA Stock Report

Market Cap

US$54.3m

7D

-1.0%

1Y

-60.5%

Updated

16 Sep, 2021

Data

Company Financials +
IDRA fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance3/6
Financial Health6/6
Dividends0/6

IDRA Overview

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology and rare disease indications in the United States.

Price History & Performance

Summary of all time highs, changes and price drops for Idera Pharmaceuticals
Historical stock prices
Current Share PriceUS$1.03
52 Week HighUS$0.97
52 Week LowUS$6.14
Beta1.81
1 Month Change-0.96%
3 Month Change-11.21%
1 Year Change-60.54%
3 Year Change-87.62%
5 Year Change-95.38%
Change since IPO-99.97%

Recent News & Updates

Shareholder Returns

IDRAUS BiotechsUS Market
7D-1.0%-1.0%-0.6%
1Y-60.5%24.9%33.7%

Return vs Industry: IDRA underperformed the US Biotechs industry which returned 23.4% over the past year.

Return vs Market: IDRA underperformed the US Market which returned 30.7% over the past year.

Price Volatility

Is IDRA's price volatile compared to industry and market?
IDRA volatility
IDRA Beta1.81
Industry Beta1.03
Market Beta1

Stable Share Price: IDRA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: IDRA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
198932Vinnie, Vin Milanohttps://www.iderapharma.com

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology and rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration and supply agreement with AbbVie Inc. and Bristol-Meyers Squibb.

Idera Pharmaceuticals Fundamentals Summary

How do Idera Pharmaceuticals's earnings and revenue compare to its market cap?
IDRA fundamental statistics
Market CapUS$54.34m
Earnings (TTM)US$8.20m
Revenue (TTM)n/a

6.6x

P/E Ratio

0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IDRA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$12.58m
Gross Profit-US$12.58m
Expenses-US$20.78m
EarningsUS$8.20m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.20
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did IDRA perform over the long term?

See historical performance and comparison

Valuation

Is Idera Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

6.63x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IDRA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IDRA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IDRA is good value based on its PE Ratio (6.6x) compared to the US Biotechs industry average (24.4x).

PE vs Market: IDRA is good value based on its PE Ratio (6.6x) compared to the US market (17.1x).


Price to Earnings Growth Ratio

PEG Ratio: IDRA's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: IDRA is good value based on its PB Ratio (1.4x) compared to the US Biotechs industry average (3.1x).


Future Growth

How is Idera Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-87.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IDRA's earnings are forecast to decline over the next 3 years (-47.7% per year).

Earnings vs Market: IDRA's earnings are forecast to decline over the next 3 years (-47.7% per year).

High Growth Earnings: IDRA's earnings are forecast to decline over the next 3 years.

Revenue vs Market: IDRA is forecast to have no revenue next year.

High Growth Revenue: IDRA is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if IDRA's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Idera Pharmaceuticals performed over the past 5 years?

-1.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IDRA has a large one-off loss of $77.3M impacting its June 30 2021 financial results.

Growing Profit Margin: IDRA became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: IDRA has become profitable over the past 5 years, growing earnings by -1.4% per year.

Accelerating Growth: IDRA has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: IDRA has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: IDRA's Return on Equity (29%) is considered high.


Financial Health

How is Idera Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: IDRA's short term assets ($43.5M) exceed its short term liabilities ($6.0M).

Long Term Liabilities: IDRA's short term assets ($43.5M) exceed its long term liabilities ($656.0K).


Debt to Equity History and Analysis

Debt Level: IDRA is debt free.

Reducing Debt: IDRA has no debt compared to 5 years ago when its debt to equity ratio was 1%.

Debt Coverage: IDRA has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: IDRA has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Idera Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IDRA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IDRA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IDRA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IDRA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IDRA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.9yrs

Average management tenure


CEO

Vinnie, Vin Milano (57 yo)

6.75yrs

Tenure

US$1,347,070

Compensation

Mr. Vincent J. Milano, also known as Vinnie and Vin, has been a Director of BioCryst Pharmaceuticals, Inc. since July 26, 2021. He has been an Independent Director at Aclaris Therapeutics, Inc. since Janua...


CEO Compensation Analysis

Compensation vs Market: Vinnie, Vin's total compensation ($USD1.35M) is above average for companies of similar size in the US market ($USD545.00K).

Compensation vs Earnings: Vinnie, Vin's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: IDRA's management team is considered experienced (2.9 years average tenure).


Board Members

Experienced Board: IDRA's board of directors are considered experienced (5.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: IDRA insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 49.9%.


Top Shareholders

Company Information

Idera Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Idera Pharmaceuticals, Inc.
  • Ticker: IDRA
  • Exchange: NasdaqCM
  • Founded: 1989
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$54.345m
  • Shares outstanding: 52.76m
  • Website: https://www.iderapharma.com

Number of Employees


Location

  • Idera Pharmaceuticals, Inc.
  • 505 Eagleview Boulevard
  • Suite 212
  • Exton
  • Pennsylvania
  • 19341
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/16 04:58
End of Day Share Price2021/09/15 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.